Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a highly conserved, multifunctional enzyme best known for its central role in glycolysis. It catalyzes the sixth step of glycolysis, converting glyceraldehyde-3-phosphate (G3P) into 1,3-bisphosphoglycerate with the concomitant reduction of NAD+ to NADH. While GAPDH’s primary function is in glycolysis, it also has several non-glycolytic roles, including regulation of cell death and survival pathways, participation in nuclear functions such as DNA repair, and interaction with other proteins affecting cellular fate under stress conditions. Altered expression or activity of GAPDH has been implicated in various diseases, including cancer, neurodegenerative diseases, and diabetes.
Inhibition of enzymatic activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH).